原始来源记录
决策级顶线结果
Invivyd：VYD2311的DECLARATION 3期试验主要数据预计于2026年年中公布
Invivyd宣布，VYD2311的DECLARATION 3期关键临床试验的主要数据预计将于2026年年中公布。该试验正在评估VYD2311用于预防COVID-19。已完成全部入组，独立数据监查委员会已建议允许孕妇和哺乳期妇女入组。
关键事实
- 申报时间
- 2026年3月5日 12:11
- 事件
- 顶线结果
- 方向
- 中性
- 来源
- SEC 8-K
- 可信度
- 有来源
来源摘录
EX-99.1 2 d118119dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates • Achieved Q4 2025 PEMGARDA ® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter • 2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025 • Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025 • DECLARATION trial on track with full enrollment achieved • DEC